Oncolytics Biotech Inc T.ONC

Novartis US$2.9 Billion MorphoSys BET Inhibitor safety issue

[Noteable]

October 29, 2024 - Novartis’ 2.7 billion euro ($2.9 billion) gamble on MorphoSys has hit turbulence. Months after buying the biotech, Novartis has revealed a safety signal that could set back plans to seek approval for the jewel of the acquisition by a couple of years.

MorphoSys linked the BET inhibitor to a reduction in spleen volume but failed to show a significant effect on symptoms, causing one hit and one miss on key endpoints.

https://www.fiercebiotech.com/biotech/novartis-29b-morphosys-bet-stumbles-safety-signal-delays-filing-years

[Noteable]

Despite handing over 2.7 billion euros ($2.9 billion) cash to buy out the German biotech in February, the star of the show in Novartis’ eyes was always pelabresib, according to deal-related documents published yesterday. MorphoSys had been testing the BET inhibitor in combination with Incyte’s Jakafi in patients with myelofibrosis. https://www.fiercebiotech.com/biotech

[Noteable]

November 21, 2023 -  MorphoSys CEO Jean-Paul Kress’ words are coming back to haunt him. The MorphoSys CEO has previously said AbbVie “failed” its phase 3 myelofibrosis trial because the Big Pharma missed one of two endpoints. Now, Kress is defending MorphoSys’ similarly mixed data on its $1.7 billion rival. The data come from a phase 3 clinical trial of pelabresib, a BET inhibitor

[Noteable]

https://www.fiercebiotech.com/biotech/after-incytes-commercial-buy-novartis-shells-out-eu27b-newly-re-clinical-morphosys

[Noteable]

October 29, 2024 - Novartis recently recorded an $800 million impairment on its MorphoSys acquisition, just five months after closing the $2.9 billion deal.    Details When October 29, 2024 Amount

[Noteable]

Regarding regulation of the immune response, the BET proteins are essential for the transcription of several inflammation-related genes and have therefore been targets of interest in drug development for inflammatory diseases and cancer. In October 2023 Roche acquired Telavant Holdings, for US$71. Billion, which is developing therapies for inflammatory disease.  https://www.mnaport.com/en

[Noteable]

Most colorectal cancer (CRC) patients are insensitive to immune checkpoint inhibitors (ICIs) due to the immunosuppressive tumor microenvironment (TME). Epigenetic factors such as the bromo-and extraterminal domain (BET) family proteins may be responsible for the immunosuppressive microenvironment. Previous studies have shown that inhibitors of BET family proteins have the potential to remodel the